Company Botanix Pharmaceuticals Limited

BOT

AU000000BOT2

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Specialty & Advanced Pharmaceuticals

Delayed Australian S.E. Other stock markets 11:29:16 14/05/2024 am IST			5-day change	1st Jan Change
0.27 ^AUD	-3.57%		+1.85%	+44.74%

13/05	Euroz Hartleys Adjusts Botanix Pharmaceutical’s Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy	MT
18/03	Botanix Pharmaceuticals Limited(ASX:BOT) added to S&P/ASX All Ordinaries Index	CI

Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. It also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. It also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

Managers	Title	Age	Since
Howie McKibbon CEO	Chief Executive Officer	-	01/19/01
Vincent Ippolito CHM	Chairman	65	20/19/20
Clarence L. Young CTO	Chief Tech/Sci/R&D Officer	68	01/21/01
Henry Bosch BRD	Director/Board Member	-	01/16/01
Jack Hoblitzell PRN	Corporate Officer/Principal	-	24/21/24
Anthony Robinson PRN	Corporate Officer/Principal	-	01/21/01
Susan Park SEC	Corporate Secretary	49	17/23/17

Members of the board	Title	Age	Since
Stewart Washer BRD	Director/Board Member	54	21/19/21
Henry Bosch BRD	Director/Board Member	-	01/16/01
Vincent Ippolito CHM	Chairman	65	20/19/20
Matthew Callahan FOU	Founder	51	01/16/01
Daniel Sharp BRD	Director/Board Member	-	22/22/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,547,144,642	1,319,431,449 ( 85.28 %)	0	85.28 %

Name	Equities	%	Valuation
INSIGNIA FINANCIAL LTD. 7.129 %	112,295,811	7.129 %	16 M $
Shenasaby Investments Pty Ltd. 4.735 %	74,586,791	4.735 %	11 M $
Caperi Pty Ltd. 3.338 %	52,573,784	3.338 %	8 M $
Antares Capital Partners Ltd. 1.184 %	18,643,553	1.184 %	3 M $
Yarraandoo Pty Ltd. 0.8253 %	13,000,000	0.8253 %	2 M $
Vincent Ippolito 0.6858 %	10,801,644	0.6858 %	2 M $
Moffatt Investments Pty Ltd. 0.6349 %	10,000,000	0.6349 %	1 M $
Gary Charles Jones 0.5714 %	9,000,000	0.5714 %	1 M $
Lightview Asset Pty Ltd. 0.5414 %	8,527,939	0.5414 %	1 M $
Stephane Nicolas Faydherbe 0.4516 %	7,113,141	0.4516 %	1 M $

Botanix Pharmaceuticals Ltd.

661 Newcastle Street Unit D2

6007, Leederville

http://www.botanixpharma.com

address Botanix Pharmaceuticals Limited(BOT)

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
BOTANIX PHARMACEUTICALS LIMITED	+44.74%	291M
MERCK KGAA	+7.22%	72.5B
KYOWA KIRIN CO. LTD.	+13.86%	9.11B
SK BIOPHARMACEUTICALS CO., LTD.	-11.75%	5.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+59.61%	5.01B
YUHAN CORPORATION	+2.62%	3.85B
BETTA PHARMACEUTICALS CO., LTD.	-17.54%	2.46B
INDIVIOR PLC	+21.35%	2.44B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-27.82%	2.26B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+25.13%	2.27B

Specialty & Advanced Pharmaceuticals